Bank of America Spends $250M Annually on GLP-1 Weight-Loss Drugs
CEO reveals the bank shells out $250 million yearly on GLP-1 medications like Ozempic for its workforce as employer costs surge.
Bank of America spends $250 million per year covering GLP-1 drugs such as Ozempic and Wegovy for its employees, CEO Brian Moynihan disclosed, underscoring the massive financial burden that blockbuster weight-loss and diabetes medications are placing on major U.S. employers.
The staggering figure highlights a broader corporate reckoning unfolding across American business. GLP-1 receptor agonists, once prescribed primarily for Type 2 diabetes, have exploded in demand as their effectiveness for weight loss became widely recognized. Individual courses of treatment can run thousands of dollars per patient each year, forcing companies to decide whether — and how much — to subsidize access for workers.
Read more ATIS Acquires Buckley Belcher to Boost Elevator Consulting Arm →
Bank of America employs roughly 213,000 people globally, making its $250 million annual GLP-1 outlay one of the largest publicly disclosed figures by any single employer. The number signals how deeply these medications have penetrated mainstream employee benefits, moving from a niche clinical offering to a significant line item in corporate health budgets.
For benefits managers and CFOs nationwide, the disclosure is a benchmark moment. Large employers are increasingly caught between containing healthcare costs and meeting worker expectations for comprehensive coverage. As GLP-1 prescriptions continue to climb, analysts expect pressure on employer-sponsored health plans to intensify, potentially reshaping how companies negotiate drug pricing and structure wellness incentives in the years ahead.
Continue reading at US Top News and Analysis.
